Immune Netw.  2015 Apr;15(2):51-57. 10.4110/in.2015.15.2.51.

Recent Advances of Vaccine Adjuvants for Infectious Diseases

• Lee S
• Nguyen MT

• KMID: 2168029
• DOI: http://doi.org/10.4110/in.2015.15.2.51

Abstract

Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.

Keyword

Vaccine; Adjuvant; Infectious disease; Innate immunity; Adaptive immunity

MeSH Terms

Adaptive Immunity
Adjuvants, Immunologic
Communicable Diseases*
Humans
Immunity, Innate
Vaccine Potency
Vaccines
Adjuvants, Immunologic
Vaccines

Reference

1. Fauci AS. Infectious diseases: considerations for the 21st century. Clin Infect Dis. 2001; 32:675–685.

2. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine. 2010; 28:Suppl 3. C25–C36.

3. Chan EH, Brewer TF, Madoff LC, Pollack MP, Sonricker AL, Keller M, Freifeld CC, Blench M, Mawudeku A, Brownstein JS. Global capacity for emerging infectious disease detection. Proc Natl Acad Sci U S A. 2010; 107:21701–21706.

4. WHO Ebola Response Team. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med. 2014; 371:1481–1495.

5. Riese P, Schulze K, Ebensen T, Prochnow B, Guzman CA. Vaccine adjuvants: key tools for innovative vaccine design. Curr Top Med Chem. 2013; 13:2562–2580.

6. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007; 57:552–556.

7. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013; 19:1597–1608.

8. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes. XVII-XXIV. J Pathol Bacteriol. 1926; 29:31–40.

9. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett. 2006; 102:10–15.

10. Lindblad EB. Aluminium adjuvants--in retrospect and prospect. Vaccine. 2004; 22:3658–3668.

11. Glenny AT, Pope CG. The antigenic effect of intravenous injection of diphtheria toxin. J Pathol Bacteriol. 1925; 28:273–278.

12. Hutchison S, Benson RA, Gibson VB, Pollock AH, Garside P, Brewer JM. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012; 26:1272–1279.

13. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol. 2013; 4:114.

14. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009; 9:287–293.

15. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009; 30:23–32.

16. Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 1998; 32:155–172.

17. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine. 2012; 30:4341–4348.

18. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001; 19:2673–2680.

19. Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract. 2010; 64:432–438.

20. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De GE, Seubert A, Wack A. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 2011; 29:1812–1823.

21. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59(®) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 2013; 12:13–30.

22. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garcon N, Van MM. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29:2461–2473.

23. Brito LA, O'Hagan DT. Designing and building the next generation of improved vaccine adjuvants. J Control Release. 2014; 190:563–579.

24. Almeida JD, Edwards DC, Brand CM, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet. 1975; 2:899–901.

25. Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines. 2007; 6:711–721.

26. Cusi MG. Applications of influenza virosomes as a delivery system. Hum Vaccin. 2006; 2:1–7.

27. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001; 1:135–145.

28. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33:492–503.

29. Gustafson GL, Rhodes MJ. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol. 1992; 143:483–488.

30. Garcon N, Chomez P, Van MM. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6:723–739.

31. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009; 5:332–340.

32. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther. 2008; 8:235–247.

33. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van MM, Garcon N. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009; 183:6186–6197.

34. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006; 5:471–484.

35. Eng NF, Bhardwaj N, Mulligan R, az-Mitoma F. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum Vaccin Immunother. 2013; 9:1661–1672.

36. Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Ther Clin Risk Manag. 2009; 5:125–132.

37. Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 2011; 239:178–196.

38. Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine. 2012; 30:5761–5769.

39. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine. 2011; 29:5145–5152.

40. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984; 308:457–460.

41. Garcia A, De Sanctis JB. An overview of adjuvant formulations and delivery systems. APMIS. 2014; 122:257–267.

42. Lovgren BK, Morein B, Osterhaus AD. ISCOM technology-based Matrix MTM adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011; 10:401–403.

43. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine. 2010; 28:5135–5144.

44. Oleszycka E, Lavelle EC. Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol. 2014; 28:1–5.

45. De GE, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 2008; 38:2068–2071.

46. O'Hagan DT, Ott GS, Van NG. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today. 1997; 3:69–75.

47. Garcon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012; 11:349–366.

48. Atmar RL, Keitel WA. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009; 333:323–344.

49. Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014; 2:159–182.

50. Moser C, Muller M, Kaeser MD, Weydemann U, Amacker M. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013; 12:779–791.

51. Garcon N, Wettendorff M, Van MM. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther. 2011; 11:667–677.